Compass Therapeutics’ (CMPX) Buy Rating Reiterated at D. Boral Capital

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They currently have a $32.00 price objective on the stock.

CMPX has been the subject of several other reports. Guggenheim started coverage on shares of Compass Therapeutics in a report on Monday. They set a “buy” rating and a $12.00 price objective for the company. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Piper Sandler began coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price on the stock. Jefferies Financial Group lifted their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Finally, Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.38.

Compass Therapeutics Price Performance

NASDAQ:CMPX opened at $3.14 on Tuesday. Compass Therapeutics has a 1-year low of $0.76 and a 1-year high of $4.08. The firm’s 50-day moving average price is $2.46 and its 200-day moving average price is $1.90. The company has a market capitalization of $431.48 million, a PE ratio of -8.47 and a beta of 1.17.

Institutional Trading of Compass Therapeutics

A number of institutional investors have recently bought and sold shares of CMPX. Rhumbline Advisers lifted its position in Compass Therapeutics by 3.1% during the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock worth $187,000 after acquiring an additional 3,822 shares during the period. Invesco Ltd. boosted its position in Compass Therapeutics by 11.3% in the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock worth $57,000 after purchasing an additional 4,018 shares in the last quarter. SG Americas Securities LLC increased its holdings in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after buying an additional 5,515 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Compass Therapeutics by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after acquiring an additional 6,041 shares during the period. Finally, ProShare Advisors LLC boosted its position in Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock worth $42,000 after purchasing an additional 9,451 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.